Advertisement

Nonadherence in Childhood Disorders: Attention-Deficit/Hyperactivity Disorder

  • Joseph C. BladerEmail author
Chapter

Abstract

Despite effective treatments for attention-deficit/hyperactivity disorder to significantly ameliorate symptoms and improve quality of life for patients and families, treatment adherence and continuity are frequently inadequate to yield satisfactory outcomes. This chapter describes attention-deficit/hyperactivity disorder, its course, and features of its optimal treatment; reviews data on pharmacotherapy adherence; and discusses factors influencing treatment adherence, including those pertaining to the medication regimen, service delivery, patient characteristics, family factors, and developmental issues. Adherence improves when diagnostic evaluations are thorough rather than perfunctory, and with simpler medication regimens, prompt follow-up to adjust treatment and address adverse effects, and ongoing encouragement of communication and concerns by parents and patients.

Keywords

Attention-deficit/hyperactivity disorder Stimulant medications; atomoxetine; clonidine; guanfacine Treatment adherence Child and adolescent mental health Pediatrics 

References

  1. 1.
    Barkley RA. Emotional dysregulation is a core component of ADHD. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 4th ed. New York: Guilford Press; 2015. p. 81–115.Google Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.Google Scholar
  3. 3.
    Bonvicini C, Faraone SV, Scassellati C. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016;21(7):872–84.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Zhu JL, Olsen J, Liew Z, Li J, Niclasen J, Obel C. Parental smoking during pregnancy and ADHD in children: the Danish National Birth Cohort. Pediatr Dent. 2014;134(2):e382–8.Google Scholar
  5. 5.
    Sibley MH, Swanson JM, Arnold LE, Hechtman LT, Owens EB, Stehli A, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry. 2017;58(6):655–62.PubMedGoogle Scholar
  6. 6.
    Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996.PubMedGoogle Scholar
  8. 8.
    The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073–86.Google Scholar
  9. 9.
    Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality, Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatr Dent. 2011;128(5):1007–22.Google Scholar
  10. 10.
    DiMatteo MR, Haskard-Zolnierek KB, Martin LR. Improving patient adherence: a three-factor model to guide practice. Health Psychol Rev. 2012;6(1):74–91.Google Scholar
  11. 11.
    Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–8.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatr Dent. 2003;112(5):e404.Google Scholar
  13. 13.
    Vitiello B, Severe JB, Greenhill LL, Arnold E, Abikoff HB, Bukstein O, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40:188–96.PubMedGoogle Scholar
  14. 14.
    Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord. 2007;11(2):157–66.PubMedGoogle Scholar
  15. 15.
    Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev Neurother. 2008;8(10):1563–71.PubMedGoogle Scholar
  16. 16.
    Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Mental Health. 2016;21(4):192–200.Google Scholar
  17. 17.
    Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) – a pharmacoepidemiological and qualitative study. Health Technol Assess. 2009;13(50):iii–iv, ix–xi, 1–120.PubMedGoogle Scholar
  18. 18.
    Zetterqvist J, Asherson P, Halldner L, Langstrom N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128(1):70–7.PubMedGoogle Scholar
  19. 19.
    Lambert MC, Reid R, Prosser B, Bussing R. A survival analysis of psychostimulant prescriptions in New South Wales from 1990 to 2010. J Child Adolesc Psychopharmacol. 2015;25(6):475–81.PubMedGoogle Scholar
  20. 20.
    Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):791–815.PubMedGoogle Scholar
  21. 21.
    Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities. Curr Psychiatry Rep. 2013;15(7):371–8. Article no. 371.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009;48(5):501–10.PubMedGoogle Scholar
  23. 23.
    Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11–21.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Lawson KA, Johnsrud M, Hodgkins P, Sasane R, Crismon ML. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther. 2012;34(4):944–956.e4.PubMedGoogle Scholar
  25. 25.
    Marcus SC, Durkin M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(5):480–9.PubMedGoogle Scholar
  26. 26.
    Hodgkins P, Sasane R, Christensen L, Harley C, Liu F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin. 2011;27(Suppl 2):53–62.PubMedGoogle Scholar
  27. 27.
    Lachaine J, Beauchemin C, Sasane R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med. 2012;124(3):139–48.PubMedGoogle Scholar
  28. 28.
    Palli SR, Kamble PS, Chen H, Aparasu RR. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(2):139–48.PubMedGoogle Scholar
  29. 29.
    Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977–89.PubMedGoogle Scholar
  30. 30.
    Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42(1):24–31.PubMedGoogle Scholar
  31. 31.
    Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60(2):204–11.PubMedGoogle Scholar
  32. 32.
    Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry. 2009;48(1):51–9.PubMedGoogle Scholar
  33. 33.
    McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry. 2012;12:219.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572–8.PubMedGoogle Scholar
  35. 35.
    Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, et al. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Psychiatry Clin Neurosci. 2012;66(1):53–63.PubMedGoogle Scholar
  36. 36.
    Adler LA, Lynch LR, Shaw DM, Wallace SP, Ciranni MA, Briggie AM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med. 2011;123(5):71–9.PubMedGoogle Scholar
  37. 37.
    Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22(7):603–11.PubMedGoogle Scholar
  38. 38.
    Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174–87.PubMedGoogle Scholar
  39. 39.
    Wehmeier PM, Dittmann RW, Banaschewski T. Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study. Atten Defic Hyperact Disord. 2015;7(2):165–74.PubMedGoogle Scholar
  40. 40.
    Brinkman WB, Baum R, Kelleher KJ, Peugh J, Gardner W, Lichtenstein P, et al. Relationship between attention-deficit/hyperactivity disorder care and medication continuity. J Am Acad Child Adolesc Psychiatry. 2016;55(4):289–94.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Naenen-Hernani K, Palazon-Bru A, Colomina-Climent F, Gil-Guillen VF, GAIPNA (Alicante Research Group in Child and Adolescent Psychiatry). Influence of written informed consent for methylphenidate on medicine persistence rates in children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2017;38(8):603–10.PubMedGoogle Scholar
  42. 42.
    Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459–68.PubMedGoogle Scholar
  43. 43.
    Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? Clin Pediatr. 2012;51(8):763–9.Google Scholar
  44. 44.
    Rashid MA, Lovick S, Llanwarne NR. Medication-taking experiences in attention deficit hyperactivity disorder: a systematic review. Fam Pract. 2018;35(2):142–50.PubMedGoogle Scholar
  45. 45.
    Ahmed R, Borst J, Wei YC, Aslani P. Parents’ perspectives about factors influencing adherence to pharmacotherapy for ADHD. J Atten Disord. 2017;21(2):91–9.PubMedGoogle Scholar
  46. 46.
    Braun S, Russo L, Zeidler J, Linder R, Hodgkins P. Descriptive comparison of drug treatment-persistent, −nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany. [Erratum appears in Clin Ther. 2016 May;38(5):1254–1258; PMID: 27136713]. Clin Ther. 2013;35(5):673–85.PubMedGoogle Scholar
  47. 47.
    Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.PubMedGoogle Scholar
  48. 48.
    Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46(8):989–1002.PubMedGoogle Scholar
  49. 49.
    Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006;16(3):286–97.PubMedGoogle Scholar
  50. 50.
    dosReis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW Jr, Ellwood LC. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2003;24(3):155–62.PubMedGoogle Scholar
  51. 51.
    Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol. 2009;19(6):673–81.PubMedGoogle Scholar
  52. 52.
    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed on August 28, 2018.Google Scholar
  53. 53.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.PubMedGoogle Scholar
  54. 54.
    Leslie LK, Plemmons D, Monn AR, Palinkas LA. Investigating ADHD treatment trajectories: listening to families’ stories about medication use. J Dev Behav Pediatr. 2007;28(3):179–88.PubMedGoogle Scholar
  55. 55.
    Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatry. 2001;9(5):223–33.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Meadows Foundation & Semp Russ Professor of Child Psychiatry, Departments of Psychiatry and PediatricsUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations